Zio AT ECG Monitoring System vs iCAC Device

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Zio AT ECG Monitoring System

by iRhythm Technologies, Inc.

iCAC Device

by Bunkerhill Health

AI Verdict

While both tools leverage AI for cardiology applications and are FDA-cleared, they address distinct clinical needs. The Zio AT ECG Monitoring System is designed for continuous, long-term arrhythmia detection via wearable ECG, whereas the iCAC Device analyzes existing CT scans to quantify coronary artery calcium for cardiovascular disease risk assessment. Therefore, they are not direct competitors but rather complementary tools within the broader field of cardiology.

Choose Zio AT ECG Monitoring System if…

Choose the Zio AT ECG Monitoring System if you require continuous, long-term cardiac rhythm monitoring to detect intermittent or asymptomatic arrhythmias. This system is ideal for patients experiencing symptoms suggestive of an arrhythmia or those at risk who need extended observation beyond a standard Holter monitor's capabilities.

View Zio AT ECG Monitoring System →

Choose iCAC Device if…

Choose the iCAC Device if you want to opportunistically assess cardiovascular disease risk by analyzing existing non-contrast, non-gated chest CT scans for coronary artery calcium. This tool is best suited for identifying patients who may benefit from further cardiovascular evaluation without the need for a dedicated cardiac CT scan.

View iCAC Device →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Zio AT ECG Monitoring System	iCAC Device
Pricing	Contact for pricing	Contact for pricing
Deployment	Cloud-based (data analytics and clinician portal)	Software as a Medical Device (SaMD), integrates with PACS or DICOM router. Cloud-based (via Carebricks platform).
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Zio AT ECG Monitoring System

Tool A offers a comprehensive ecosystem for both patients and clinicians, including a wearable device, a patient mobile app for symptom logging and education, and a clinician portal/app. This broader user engagement and direct patient interaction suggest a higher degree of overall usability. Tool B, while integrating into existing radiology workflows, does not detail a similar breadth of user-facing tools.

Clinical Value

Tie

Both tools are FDA-cleared and provide significant clinical value in cardiology, albeit at different points in the care continuum. Tool A offers continuous, AI-powered monitoring for active arrhythmia diagnosis and detection of asymptomatic events. Tool B provides opportunistic early detection and quantification of cardiovascular disease risk from existing imaging, both contributing substantially to improved patient outcomes.

Pricing & Value

Tie

Neither tool provides publicly disclosed pricing information, making a direct comparison of their cost-effectiveness or overall value proposition impossible. Both require direct vendor contact for pricing details, which prevents an objective assessment in this dimension.

Enterprise Readiness

Zio AT ECG Monitoring System

Tool A explicitly states it has a Business Associate Agreement (BAA) and is HIPAA compliant, which are critical for enterprise adoption in healthcare. Tool B requires contacting the vendor for these crucial compliance details, indicating a potential lack of transparency or readily available documentation for enterprise stakeholders.

Innovation

iCAC Device

Tool B demonstrates significant innovation by leveraging existing, routine imaging data (non-contrast, non-gated chest CTs) to opportunistically identify and quantify coronary artery calcium. This approach offers a novel way to screen for cardiovascular disease risk without requiring additional dedicated scans, enhancing efficiency and potentially reducing costs. Tool A's innovation lies in its continuous, long-term wearable monitoring, but Tool B's opportunistic screening from existing data is a distinct and impactful innovation.

Support & Docs

Zio AT ECG Monitoring System

Tool A's description includes dedicated clinician and patient mobile apps that offer features like symptom logging and education, suggesting a more comprehensive and accessible support and documentation ecosystem built into the product. Tool B's information focuses on technical integration with EHRs without detailing similar user-facing support resources or educational content.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Zio AT ECG Monitoring System	iCAC Device
Name	Zio AT ECG Monitoring System	iCAC Device
Company	iRhythm Technologies, Inc.	Bunkerhill Health
Core Functionality	Continuous, AI-powered ECG monitoring for long-term arrhythmia detection and comprehensive reporting.	Detects and quantifies coronary artery calcium from routine, non-contrast, non-gated chest CT scans, aiding in early cardiovascular disease detection.
Input Data Type	Wearable Zio AT patch for continuous ECG recording	Routine, non-contrast, non-gated chest CT scans
Output/Report Type	Comprehensive end-of-wear reports for clinicians, ZioSuiteu00ae clinician portal and mobile app, MyZiou00ae patient mobile app.	Visual representation of estimated CAC segmentation, exact and four-category quantitative estimates of CAC burden in Agatston units, integrates with EHRs.
Specialties	Cardiology	Cardiology, Radiology

Videos

Demos, reviews, and walkthroughs featuring Zio AT ECG Monitoring System and iCAC Device.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows, and for what specific patient populations or diagnostic pathways are they best suited?

The Zio AT system involves a wearable patch for continuous ECG monitoring, ideal for long-term arrhythmia detection in patients with symptomatic or asymptomatic cardiac events. The iCAC Device analyzes routine, non-contrast chest CT scans to opportunistically identify and quantify coronary artery calcium, aiding in early cardiovascular disease detection from existing imaging data.

What is the depth of EHR integration for each tool, specifically regarding data flow and accessibility of results for clinicians?

The Zio AT system provides comprehensive end-of-wear reports accessible via the ZioSuite clinician portal and mobile app, with integration options to streamline ordering and results directly into EHRs. The iCAC Device integrates with EHRs via the Carebricks platform, delivering visual representations and quantitative estimates of CAC burden directly into the patient record.

Can you elaborate on the accuracy and specific clinical outputs of each tool's AI algorithm for its respective diagnostic purpose?

The Zio AT system utilizes an FDA-cleared deep-learned AI algorithm (ZEUS System) for continuous, uninterrupted ECG recording and detection of symptomatic and asymptomatic cardiac events. The iCAC Device employs FDA-cleared deep-learning algorithms to provide exact and four-category quantitative estimates of CAC burden in Agatston units, along with visual segmentations from routine CT scans.

How do the primary user interfaces and target specialties of each tool influence the expected learning curve for physicians and their staff?

The Zio AT system, primarily for Cardiology, uses the ZioSuite clinician portal and mobile app for patient management and report interpretation, suggesting a learning curve associated with a new digital platform. The iCAC Device, relevant for both Cardiology and Radiology, integrates as a Software as a Medical Device with PACS or DICOM routers, providing adjunctive information to radiologists within their existing imaging workflow.

For healthcare systems considering a multi-site rollout, what are the key logistical and technical considerations for implementing each tool across different clinics or hospitals?

Implementing the Zio AT system involves managing the distribution and return of wearable patches and ensuring wireless data transmission across multiple sites. The iCAC Device, as a Software as a Medical Device, requires technical integration with existing PACS or DICOM router infrastructure at each facility.

What is the fundamental difference in how each tool supports cardiovascular disease management u2013 through proactive monitoring versus opportunistic detection?

The Zio AT system offers proactive, continuous ECG monitoring for up to 14 days to detect arrhythmias, enabling timely intervention for cardiac events. In contrast, the iCAC Device provides opportunistic detection by analyzing existing, routine chest CT scans to identify coronary artery calcium, leveraging incidental findings for early cardiovascular risk assessment.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Zio AT ECG Monitoring System or iCAC Device

Backers

Who funded each tool's parent company.